H-Leu-OH

CAS# 61-90-5

H-Leu-OH

Catalog No. BCC2968----Order now to get a substantial discount!

Product Name & Size Price Stock
H-Leu-OH: 5mg $6 In Stock
H-Leu-OH: 10mg Please Inquire In Stock
H-Leu-OH: 20mg Please Inquire Please Inquire
H-Leu-OH: 50mg Please Inquire Please Inquire
H-Leu-OH: 100mg Please Inquire Please Inquire
H-Leu-OH: 200mg Please Inquire Please Inquire
H-Leu-OH: 500mg Please Inquire Please Inquire
H-Leu-OH: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of H-Leu-OH

Number of papers citing our products

Chemical structure

H-Leu-OH

3D structure

Chemical Properties of H-Leu-OH

Cas No. 61-90-5 SDF Download SDF
PubChem ID 6106 Appearance Powder
Formula C6H13NO2 M.Wt 131.2
Type of Compound Alkaloids Storage Desiccate at -20°C
Synonyms L-leucine; Leucine; 61-90-5; (S)-Leucine; (S)-2-Amino-4-methylpentanoic acid;
Solubility H2O : 8.33 mg/mL (63.51 mM; Need ultrasonic)
Chemical Name (2S)-2-amino-4-methylpentanoic acid
SMILES CC(C)CC(C(=O)O)N
Standard InChIKey ROHFNLRQFUQHCH-YFKPBYRVSA-N
Standard InChI InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of H-Leu-OH

The cultures of Corynebacterium glutamicum.

Biological Activity of H-Leu-OH

DescriptionL-Leucine is an essential amino acid for the human body, L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway, and an excess of dietary l-leucine has been shown to retard the growth of rats fed low-protein diets or diets deficient in isoleucine.
TargetsmTOR | p53
In vitro

L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.[Pubmed: 22734070 ]

Blood. 2012 Sep 13;120(11):2214-24.

Haploinsufficiency of ribosomal proteins (RPs) has been proposed to be the common basis for the anemia observed in Diamond-Blackfan anemia (DBA) and myelodysplastic syndrome with loss of chromosome 5q [del(5q) MDS]. We have modeled DBA and del(5q) MDS in zebrafish using antisense morpholinos to rps19 and rps14, respectively, and have demonstrated that, as in humans, haploinsufficient levels of these proteins lead to a profound anemia.
METHODS AND RESULTS:
To address the hypothesis that RP loss results in impaired mRNA translation, we treated Rps19 and Rps14-deficient embryos with the amino acid L-Leucine, a known activator of mRNA translation. This resulted in a striking improvement of the anemia associated with RP loss. We confirmed our findings in primary human CD34⁺ cells, after shRNA knockdown of RPS19 and RPS14. Furthermore, we showed that loss of Rps19 or Rps14 activates the mTOR pathway, and this is accentuated by L-Leucine in both Rps19 and Rps14 morphants. This effect could be abrogated by rapamycin suggesting that mTOR signaling may be responsible for the improvement in anemia associated with L-Leucine.
CONCLUSIONS:
Our studies support the rationale for ongoing clinical trials of L-Leucine as a therapeutic agent for DBA, and potentially for patients with del(5q) MDS.

In vivo

L-Leucine, an isoleucine antagonist in the rat[Reference: WebLink]

Arch Biochem Biophys. 1955 Jul;57(1):1-12.


METHODS AND RESULTS:
An excess of dietary L-Leucine has been shown to retard the growth of rats fed low-protein diets or diets deficient in isoleucine. The addition of isoleucine to such diets overcame, to a large extent, the growth-retarding action of an excess of L-Leucine.
CONCLUSIONS:
These observations suggest that an excess of dietary L-Leucine can act as an antimetabolite of isoleucine in the rat and can thereby increase the requirement of the rat for isoleucine.

Protocol of H-Leu-OH

Kinase Assay

Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome[Pubmed: 24098154 ]

PLoS Genet. 2013;9(10):e1003857.

Roberts syndrome (RBS) is a human disease characterized by defects in limb and craniofacial development and growth and mental retardation. RBS is caused by mutations in ESCO2, a gene which encodes an acetyltransferase for the cohesin complex. While the essential role of the cohesin complex in chromosome segregation has been well characterized, it plays additional roles in DNA damage repair, chromosome condensation, and gene expression. The developmental phenotypes of Roberts syndrome and other cohesinopathies suggest that gene expression is impaired during embryogenesis. It was previously reported that ribosomal RNA production and protein translation were impaired in immortalized RBS cells. It was speculated that cohesin binding at the rDNA was important for nucleolar form and function.
METHODS AND RESULTS:
We have explored the hypothesis that reduced ribosome function contributes to RBS in zebrafish models and human cells. Two key pathways that sense cellular stress are the p53 and mTOR pathways. We report that mTOR signaling is inhibited in human RBS cells based on the reduced phosphorylation of the downstream effectors S6K1, S6 and 4EBP1, and this correlates with p53 activation. Nucleoli, the sites of ribosome production, are highly fragmented in RBS cells. We tested the effect of inhibiting p53 or stimulating mTOR in RBS cells. The rescue provided by mTOR activation was more significant, with activation rescuing both cell division and cell death. To study this cohesinopathy in a whole animal model we used ESCO2-mutant and morphant zebrafish embryos, which have developmental defects mimicking RBS. Consistent with RBS patient cells, the ESCO2 mutant embryos show p53 activation and inhibition of the TOR pathway. Stimulation of the TOR pathway with L-Leucine rescued many developmental defects of ESCO2-mutant embryos.
CONCLUSIONS:
Our data support the idea that RBS can be attributed in part to defects in ribosome biogenesis, and stimulation of the TOR pathway has therapeutic potential.

Animal Research

Dietary L-leucine improves the anemia in a mouse model for Diamond-Blackfan anemia.[Pubmed: 22791294 ]

Blood. 2012 Sep 13;120(11):2225-8.

Diamond-Blackfan anemia (DBA) is a congenital erythroid hypoplasia caused by a functional haploinsufficiency of genes encoding for ribosomal proteins. Recently, a case study reported a patient who became transfusion-independent in response to treatment with the amino acid L-Leucine.
METHODS AND RESULTS:
Therefore, we have validated the therapeutic effect of L-Leucine using our recently generated mouse model for RPS19-deficient DBA. Administration of L-Leucine significantly improved the anemia in Rps19-deficient mice (19% improvement in hemoglobin concentration; 18% increase in the number of erythrocytes), increased the bone marrow cellularity, and alleviated stress hematopoiesis. Furthermore, the therapeutic response to L-Leucine appeared specific for Rps19-deficient hematopoiesis and was associated with down-regulation of p53 activity.
CONCLUSIONS:
Our study supports the rationale for clinical trials of L-Leucine as a therapeutic agent for DBA.

H-Leu-OH Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

H-Leu-OH Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of H-Leu-OH

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 7.622 mL 38.1098 mL 76.2195 mL 152.439 mL 190.5488 mL
5 mM 1.5244 mL 7.622 mL 15.2439 mL 30.4878 mL 38.1098 mL
10 mM 0.7622 mL 3.811 mL 7.622 mL 15.2439 mL 19.0549 mL
50 mM 0.1524 mL 0.7622 mL 1.5244 mL 3.0488 mL 3.811 mL
100 mM 0.0762 mL 0.3811 mL 0.7622 mL 1.5244 mL 1.9055 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on H-Leu-OH

H-Leu-OH

Featured Products
New Products
 

References on H-Leu-OH

Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome.[Pubmed:24098154]

PLoS Genet. 2013;9(10):e1003857.

Roberts syndrome (RBS) is a human disease characterized by defects in limb and craniofacial development and growth and mental retardation. RBS is caused by mutations in ESCO2, a gene which encodes an acetyltransferase for the cohesin complex. While the essential role of the cohesin complex in chromosome segregation has been well characterized, it plays additional roles in DNA damage repair, chromosome condensation, and gene expression. The developmental phenotypes of Roberts syndrome and other cohesinopathies suggest that gene expression is impaired during embryogenesis. It was previously reported that ribosomal RNA production and protein translation were impaired in immortalized RBS cells. It was speculated that cohesin binding at the rDNA was important for nucleolar form and function. We have explored the hypothesis that reduced ribosome function contributes to RBS in zebrafish models and human cells. Two key pathways that sense cellular stress are the p53 and mTOR pathways. We report that mTOR signaling is inhibited in human RBS cells based on the reduced phosphorylation of the downstream effectors S6K1, S6 and 4EBP1, and this correlates with p53 activation. Nucleoli, the sites of ribosome production, are highly fragmented in RBS cells. We tested the effect of inhibiting p53 or stimulating mTOR in RBS cells. The rescue provided by mTOR activation was more significant, with activation rescuing both cell division and cell death. To study this cohesinopathy in a whole animal model we used ESCO2-mutant and morphant zebrafish embryos, which have developmental defects mimicking RBS. Consistent with RBS patient cells, the ESCO2 mutant embryos show p53 activation and inhibition of the TOR pathway. Stimulation of the TOR pathway with L-leucine rescued many developmental defects of ESCO2-mutant embryos. Our data support the idea that RBS can be attributed in part to defects in ribosome biogenesis, and stimulation of the TOR pathway has therapeutic potential.

L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.[Pubmed:22734070]

Blood. 2012 Sep 13;120(11):2214-24.

Haploinsufficiency of ribosomal proteins (RPs) has been proposed to be the common basis for the anemia observed in Diamond-Blackfan anemia (DBA) and myelodysplastic syndrome with loss of chromosome 5q [del(5q) MDS]. We have modeled DBA and del(5q) MDS in zebrafish using antisense morpholinos to rps19 and rps14, respectively, and have demonstrated that, as in humans, haploinsufficient levels of these proteins lead to a profound anemia. To address the hypothesis that RP loss results in impaired mRNA translation, we treated Rps19 and Rps14-deficient embryos with the amino acid L-leucine, a known activator of mRNA translation. This resulted in a striking improvement of the anemia associated with RP loss. We confirmed our findings in primary human CD34(+) cells, after shRNA knockdown of RPS19 and RPS14. Furthermore, we showed that loss of Rps19 or Rps14 activates the mTOR pathway, and this is accentuated by L-leucine in both Rps19 and Rps14 morphants. This effect could be abrogated by rapamycin suggesting that mTOR signaling may be responsible for the improvement in anemia associated with L-leucine. Our studies support the rationale for ongoing clinical trials of L-leucine as a therapeutic agent for DBA, and potentially for patients with del(5q) MDS.

Dietary L-leucine improves the anemia in a mouse model for Diamond-Blackfan anemia.[Pubmed:22791294]

Blood. 2012 Sep 13;120(11):2225-8.

Diamond-Blackfan anemia (DBA) is a congenital erythroid hypoplasia caused by a functional haploinsufficiency of genes encoding for ribosomal proteins. Recently, a case study reported a patient who became transfusion-independent in response to treatment with the amino acid L-leucine. Therefore, we have validated the therapeutic effect of L-leucine using our recently generated mouse model for RPS19-deficient DBA. Administration of L-leucine significantly improved the anemia in Rps19-deficient mice (19% improvement in hemoglobin concentration; 18% increase in the number of erythrocytes), increased the bone marrow cellularity, and alleviated stress hematopoiesis. Furthermore, the therapeutic response to L-leucine appeared specific for Rps19-deficient hematopoiesis and was associated with down-regulation of p53 activity. Our study supports the rationale for clinical trials of L-leucine as a therapeutic agent for DBA.

Description

L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.

Keywords:

H-Leu-OH,61-90-5,L-leucine; Leucine; 61-90-5; (S)-Leucine; (S)-2-Amino-4-methylpentanoic acid;,Natural Products,Amino Acids and Derivatives, buy H-Leu-OH , H-Leu-OH supplier , purchase H-Leu-OH , H-Leu-OH cost , H-Leu-OH manufacturer , order H-Leu-OH , high purity H-Leu-OH

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: